Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Müge Çevik, Lindsay C Thompson, Caryn M. Upton, Valéria C. Rolla, Mookho Malahleha, Blandina T. Mmbaga, Nosipho Ngubane, Zamzurina Abu Bakar, Mohammed Rassool, Ebrahim Variava, Rodney Dawson, Suzanne Staples, Umesh Lalloo, Cheryl Louw, Francesca Conradie, Marika Eristavi, Anastasia Samoilova, Sergey Skornyakov, Niyanda Elias Ntinginya, Frederick Haraka, George PrayGod, Harriett Mayanja-Kizza, Janice Caoili, Vincent M. Balanag, Margareth Pretti Dalcolmo, Timothy D. McHugh, Robert Hunt, Priya Solanki, Matthew Bates, Angela M. Crook, Stella M. Fabiane, Juliano Timm, Eugene Sun, Melvin Spigelman, Derek J. Sloan, Stephen H. Gillespie, Paul Bruinenberg, Maria Beumont, Jerry Nedelman, Mengchun Li, Ntokozo Zuma-Gwala, Shakira Rajaram, Louise Choo, Genevive Wills, Matt Betteridge, Leandra Leandra, Morounfolu Olugbosi, Borisov Se